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Orphan diseaseResearch is an expensive venture requiring multiple sources of funding for small projects that test new the-
ories, large projects to make major advancements, training the next generation of researchers and facilitating
meetings to share ﬁndings and support collaboration. For rare conditions, such as Batten disease, research
funds can be difﬁcult to ﬁnd.
To see how investigators supported their work in the past, we did a key word search of the Acknowledge-
ment Section of peer-reviewed literature published in Batten disease in the last 6.5 years. Interestingly, we
discovered 193 separate funding sources. The authors hope that, by showing where funds are available, we
will enable Batten disease researchers to continue their pursuits and expand their studies; moving key ﬁnd-
ings from discovery to application phases. This article is part of a Special Issue entitled: The Neuronal Ceroid
Lipofuscinoses or Batten Disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Funding for scientiﬁc research typically comes from three main
sources: government agencies, such as the US National Institutes of
Health (NIH), pharmaceutical companies, and private funders includ-
ing family foundations, charities, and philanthropists. It is estimated
that federal governments provide 30% of all medical research funding
concentrating on basic research and scholarly pursuit. Pharmaceutical
and Biotechnology for-proﬁt companies are responsible for 60–65% of
research funding. These industries invest in basic discovery but focus
the bulk of their efforts on transitioning their own discoveries and
those funded by federal governments into applied medicines. Private
funding constitutes less than 5% of overall research spending. Howev-
er, private funders are in a unique position to ﬁll funding gaps and ad-
vance therapy. Because of their focus on identifying, prioritizing, and
shepherding translatable discoveries, the National Multiple Sclerosis
Society (NMSS) has played a pivotal role in bringing MS drugs to
market and the Michael J Fox Foundation (MJFF) has supported 51
clinical trials in the Parkinson disease ﬁeld. By supporting innovative
pilot studies, investing in proof-of-principal/early failure studies in
drug discovery, educating their patient communities, and developing
centralized registries, these trailblazers have set the stage for smallerJNCL, Juvenile Neuronal Ceroid
A, Batten Disease Support and
ciation
ronal Ceroid Lipofuscinoses or
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hr), contact@ncl-stiftung.de
l rights reserved.nonproﬁts to follow suit strategically placing their funds where they
are needed the most.
For legislative decision makers, clinicians, and research scientists,
rare or “orphan” diseases are deﬁned as any disease that affects a
very small percentage of the population. For families affected by
these diseases, “rare” refers to a disease in which very little academic
research takes place and has not been adopted by the pharmaceutical
industry because it offers little ﬁnancial incentive to make and market
drugs to treat and prevent it. With a prevalence rate of 1.2 per
100,000 live births, Batten disease (also known as Neuronal Ceroid
Lipofuscinosis) falls well within the deﬁnition of a rare disease in Europe
(less than 5 in 10,000). In the USA according to the Rare Disease Act of
2002 an orphan disease is deﬁned as one that affects less than 200,000
persons, which is about 1 in 1500 people [1]. In total approximately
6000–8000 rare diseases are known. Batten disease, by any deﬁnition,
is rare. The National Institutes of Health in the United States dedicated
.001% of its budget to all forms of Batten disease. The European Union
funded fewer proposals. Less than ﬁve pharmaceutical companies have
invested in 2 forms of Batten disease.
Nonproﬁt Batten disease foundations and charities have attempted
to ﬁll this gap by establishing fellowships to train new investigators,
providing high-risk pilot grants to test novel ideas, and investing in
disease-speciﬁc resources such as cell lines and animal models. If pas-
sion was equal to money, we would be rich in every sense of the
word. Unfortunately, this is not the case. Research is expensive and pri-
vate funding accounts for less that 5% of the total investment inmedical
research highlighting what an uphill battle rare disease foundations
face.
This article carefully examines the Batten disease funding landscape.
The authors hope that, by showing where funds are available, we will
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their studies, moving key ﬁndings from discovery to application phases.
2. Methods
2.1. Batten disease literature online search
For addressing the question which agencies fund speciﬁcally
Batten disease research we conducted a literature search via PubMed
(www.ncbi.nlm.nih.gov/pubmed/) using the key words “Ceroid”,
“Batten”, “Battenin”, or “Btn1” in the title as well as the abstract.
The publication dates were limited to January, 2006 and June, 2012.
Each result was analyzed for its relevance to Batten disease. Subse-
quently the “funding” or “Acknowledgement” sections (depending
on the journal) of these articles were analyzed in order to set up a
list of funding agencies. The mentioned agencies were searched on
the web and categorized by the type of organization they belong to.
3. Results
3.1. Batten disease literature online search
By using different key words relevant to Batten disease we identi-
ﬁed 449 articles listed in PubMed between January, 2006 and June,
2012. We identiﬁed between 37 and 57 publications per year
(2006–2011: average 48 SN +/− 6). Manual examination of each ab-
stract, revealed 298 publications relevant to Batten disease. False
positives were generated e.g. by articles dealing with the Hermansky
Pudlak Syndrome (13 articles), “Batten grafts” (28 articles) or “ceroid”
(62 articles) — a component of accumulated storage material found in
age-related macular degeneration as well as Batten disease. Of the 298
Batten disease publications 236were analyzed for references to funding
sources. The remaining publications (62) did not mention any funding
resources (55), did not have an “Acknowledgement” section (4), or
were not accessible to the authors (3).
We identiﬁed 193 different funding agencies that supported
Batten disease research (Fig. 1). 39% were non-proﬁt organizations.
An equal number of public funders were found. This category includes
national as well as international programs. The level of funding is not
mentioned in publications.
This study is limited to the choice of key words that have been
used. In addition, the outcome only shows agencies that funded
Batten disease research which led to a peer-reviewed publication.
Other data bases – e.g. patent data bases and commercial product an-
nouncements – were not included but could contribute to a higher
number of publications. It is unclear whether these or other publica-
tions would cite funding sources.
54% (109) of the acknowledged funding sources were mentioned
in one article, suggesting that their investment in Batten disease re-
search was a one-time investment or indirect (Supplementary mate-
rial). The NIH and Batten Disease Support and Research Association
(BDSRA) were the most acknowledged funding sources, cited 103
and 88 times respectively, followed by theWellcome Trust and Batten4%
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non-profit organizations
academic research
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Fig. 1. Categorization of 193 funding sources found in 236 articles.Disease Family Association (BDFA) (25 and 22 times respectively). In
165 out of 236 articles (~70%) at least one non-proﬁt organization
was mentioned among the funding agencies emphasizing the ﬁnan-
cial contribution of this category.
In more than 80% of 236 Batten disease publications at least two
different funding resources were mentioned (Fig. 2). This means
that researchers depend on multiple funding resources. This could
be due to the fact that research projects are accomplished by teams
of researchers with different funding needs spanning laboratories
and universities plus the high cost of research.
Examining the geographical location of corresponding authors sug-
gested that nearly 50% of Batten disease research was led by investiga-
tors inUS-based institutions (Fig. 3). The secondhighest score, from295
papers reviewed, showed active research programs in Finland where
the carrier frequency of mutated Batten disease alleles is much higher
than the known world average. In total, peer-reviewed research was
conducted by investigators in 31 countries.4. Discussion
Without attaching funding levels to various sources or being able
to ensure the accuracy of each acknowledgement section, it is impos-
sible to draw solid conclusions from this data other than several
funding sources used to complete published research in the
6.5 years we looked at. While the ratio of federal to private funding
appears near-equal, again the amounts are unknown. Future direc-
tions may include assigning funding levels. However, these numbers
can be quite volatile as availability of funds changes rapidly, especially
in the nonproﬁt sector which is highly dependent upon local economies.
Therefore, researchers and students should be encouraged to engage the
services of an online editorially-reviewed and well-maintained medical
research database network such as Community of Science (COS), now
owned by ProQuest. COS and other networks as such, allow one to save
searches, track speciﬁc opportunities, and create personal deadlines.
Duke University hosts a website (https://researchfunding.duke.edu/)
helping university-based investigators access funding opportunities
from around the world as well as local opportunities created by state
funding agencies and local supporters. Many large universities also
have dedicated staff to match opportunities to their investigators. The
ELectronic Research Funding Information System (ELFI) www.elﬁ.info/
index.php posts funding opportunities for rare disease research in
German speaking regions. It provides a well-kept collection of public
and private funding options including short descriptions. Furthermore,
the German website “Forschen–Foerdern” (www.forschen-foerdern.
org/en) provides a good overview about research awards and research
programs. Another website that might be of interest is hosted by0
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Fig. 3. Number of Batten disease articles published per country (01/2006–06/2012).
“Others”: number of publications equal or less than 10 per country. It includes 25
different countries.
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funding/resources/).
Funding opportunities can be very speciﬁc. Examples include
stipends for time spent writing medical education books, grants for
women returning to research after raising their families, or support
for members of particular religious groups. Researchers can maximize
their search for funds by informing their development ofﬁce of exact-
ly what it is that they do.
Most non-proﬁt organizations that fund research have strict regu-
lations. Most are disease or population speciﬁc (e.g. Blackswan Foun-
dation, rare disease). Many have citizenship requirements preferring
to support their own country's research needs. Some focus on the re-
search needs of a particular institution developing a more intimate
relationship with the needs of a single community.
With the advent of advanced communication systems, the ﬁeld of
research and associated nonproﬁts has gone global and it is much easier
for a nonproﬁt to act worldwide. BDSRA and Bee for Battens fund NCL
projects across the globe. NCL-Stiftung and Beyond Batten Disease
Foundation do the same for juvenile NCL.
5. Conclusion
We identiﬁed 193 different funding agencies that supported Batten
disease research. 39% were non-proﬁt organizations. An equal numberof public funders were found. The numbers of government-supported
funding sources and nonproﬁt private funds were approximately
equal. The NIH and BDSRA were the most frequent funders followed
by the Wellcome Trust and BDFA. Approximately 70% of articles cited
receiving funding from at least one non-proﬁt organization. Over 80%
of articles cited at least two different funding resources. Almost 50% of
all published articles have a corresponding author in the United States,
followed by researchers in Finland. In total, publicationswere produced
by investigators from 31 countries. In conclusion, advancements in
Batten disease research have required multiple funders willing to
make investments in laboratories across the globe. Affected families
play a major role in research not only by raising many of the nonproﬁt
funds that have been used but also by raising awareness, advocating
for increased government spending, motivating researchers, providing
valuable medical histories and submitting precious resource material
ultimately placing their trust in the research and healthcare community
to change their future.
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